Neuland Laboratories Limited has delivered a robust financial performance for the fiscal year ended March 31, 2026, reporting a consolidated annual revenue of ₹2,02,298.54 lakhs and a net profit of ₹36,399.84 lakhs. Alongside these record results, the company’s Board has recommended a final dividend of ₹34 per equity share and approved a significant ₹143.4 crore investment to expand production capacity at its Unit 1 facility.
Fiscal Year 2026 Financial Highlights
For the fiscal year ended March 31, 2026, Neuland Laboratories achieved a consolidated revenue from operations of ₹2,02,298.54 lakhs, compared to ₹1,47,683.73 lakhs in the previous year. The company reported a net profit for the year of ₹36,399.84 lakhs, marking a significant growth over the ₹26,010.81 lakhs recorded in FY25. Performance in the fourth quarter remained strong, with revenue reaching ₹77,625.03 lakhs.
Shareholder Dividends
Reflecting its strong financial health and commitment to returning value to investors, the Board of Directors has recommended a final dividend of ₹34 per equity share (340% on a face value of ₹10). The dividend is subject to approval by shareholders at the upcoming 42nd Annual General Meeting, scheduled for August 4, 2026, with a record date set for July 24, 2026.
Strategic Capacity Expansion
To support growing customer demand, the Board has approved an investment of ₹143.4 crores (including GST) to enhance production capacity at its Unit 1 location in Bonthapally, Telangana. The project will add 120.5 KL to the existing capacity of 256 KL. This expansion is expected to be completed within a timeframe of 12 to 18 months and will be funded through a combination of internal accruals and borrowings.
Leadership Update
The company also announced the appointment of Dr. Mauricio Futran as an Additional Director, categorized as a Non-Executive Non-Independent member, effective May 12, 2026. Dr. Futran brings over 40 years of extensive experience in process development and manufacturing, having previously served in leadership roles at major global pharmaceutical organizations.
Source: BSE
